COMMUNIQUÉS West-GlobeNewswire

FOXO TECHNOLOGIES INC.’S BOARD OF DIRECTORS ANNOUNCES SPECIAL MEETING OF SHAREHOLDERS

18/11/2024 - 14:30

MINNEAPOLIS, MN, Nov. 18, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold a Special Meeting of its Shareholders at 10.30am EST on Friday, November 29, 2024. The [...]

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

18/11/2024 - 14:30

SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

18/11/2024 - 14:30

BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted [...]

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

18/11/2024 - 14:30

FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel ( [...]

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

18/11/2024 - 14:30

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava’s commercial readiness strategy as the Company prepares for [...]

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

18/11/2024 - 14:30

Actively Exploring Partnership for Alzheimer’s Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company [...]

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

18/11/2024 - 14:30

ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine Models Proprietary Dagger ® Technology Enables ALLO-329 to Overcome [...]

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

18/11/2024 - 14:40

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal [...]

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

18/11/2024 - 14:45

- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo – - Top-line [...]

SoldierStrong Announces Annual SoldierScholar Recipients for 2024

18/11/2024 - 15:00

STAMFORD, Conn., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Delivering on its commitment to assist military veterans in taking a significant academic step forward in life after service, the national nonprofit SoldierStrong today [...]

Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease

18/11/2024 - 15:16

Designations underscore significant unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists. Data from Alkeus’ TEASE program were presented at the American Academy of [...]

Novo Nordisk A/S - share repurchase programme

18/11/2024 - 16:08

Bagsværd, Denmark, 18 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA

18/11/2024 - 17:00

SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneer of AAV immuno-gene therapy for cancer, today revealed its lead asset, SRN-101, for the treatment of high-grade gliomas. The FDA granted both [...]

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

18/11/2024 - 17:15

- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at [...]

Ben Austin, CFO and COO of SPR® Therapeutics, Named to Crain’s Cleveland Business 40 Under 40 List

18/11/2024 - 17:20

CLEVELAND, Nov. 18, 2024 (GLOBE NEWSWIRE) -- For over 30 years, Crain’s Cleveland Business has recognized leading professionals in the Northeast Ohio region that have been celebrated as part of the 40 Under 40 program. [...]

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day »

18/11/2024 - 18:00

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day » Cette journée, organisée en collaboration avec Phage Canada et réunissant des experts [...]

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

18/11/2024 - 18:00

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" This event, organized in collaboration with Phage Canada and bringing together international experts, [...]

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

18/11/2024 - 21:20

– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P mean reduction [...]

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

18/11/2024 - 22:05

Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN [...]